Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics

Tamoxifen (TAM) is the most commonly used adjuvant endocrine drug for hormone receptor-positive (HR+) breast cancer patients. However, how to accurately evaluate the risk of breast cancer recurrence and metastasis after adjuvant TAM therapy is still a major concern. In recent years, many studies hav...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hui Pang, Guoqiang Zhang, Na Yan, Jidong Lang, Yuebin Liang, Xinyuan Xu, Yaowen Cui, Xueya Wu, Xianjun Li, Ming Shan, Xiaoqin Wang, Xiangzhi Meng, Jiaxiang Liu, Geng Tian, Li Cai, Dawei Yuan, Xin Wang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	breast cancer hormone receptor-positive tamoxifen risk factors risk-of-recurrence score Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5313a9c842734c44ad421fe0712d1041
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics

Ejemplares similares